Company / Shareholders' Equity
Idexx Laboratories Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$1.6B
FY2025
5-year range
$608.7M / $1.6B
FY2021-FY2025
Trend
+0.6%
vs FY2024
Sector context
#65 of 166
Health Care
What the data says
At $1.6B, Idexx Laboratories's shareholders' equity ranks #65 of 166 in the Health Care sector. Shareholders' Equity has increased for 3 consecutive years, from $609M in FY2022 to $1.6B in FY2025.
Based on SEC 10-K filings.
$1.6B in FY2025 with a 5-year CAGR of +20.5%.
Improved from $1.5B to $1.6B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +38.2%
- 5-Year CAGR
- +20.5%
- 10-Year CAGR
- -
Sector benchmark
#65 of 166 in Health CareTop 39% of 166This company $1.6B Sector average $5.3B
▼
-69.4% below sector average
Key checks
Key Insights
- Idexx Laboratories's shareholders' equity has grown for 3 consecutive years.
- 5-year CAGR of +20.5%, indicating consistent growth.
- In FY2025, shareholders' equity increased 0.6% year-over-year.
- Ranks #65 out of 166 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 4.60 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.6%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 65.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.6B | +0.6% |
| FY2024 | $1.6B | +7.5% |
| FY2023 | $1.5B | +143.9% |
| FY2022 | $608.7M | -11.8% |
| FY2021 | $690.0M | +9.2% |
| FY2020 | $632.1M | +256.2% |
| FY2019 | $177.5M | +1965.6% |
| FY2018 | -$9.5M | +82.4% |
| FY2017 | -$54.1M | +50.1% |
| FY2016 | -$108.4M | -28.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026